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Abstract
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-tryptophan
produced by fermentation with Escherichia coli CGMCC 11674 when used as a nutritional additive in
feed and water for drinking for all animal species and categories. The production strain did not raise
safety concerns. The FEEDAP Panel cannot conclude on the safety of L-tryptophan produced by E. coli
CGMCC 11674 for the target species and for the consumer due to the tryptophan-related impurities
such as 1,1’-ethylidene-bis-L-tryptophan (EBT). The FEEDAP Panel has concerns on the safety of the
simultaneous oral administration of L-tryptophan via water for drinking and feed. Using unprotected
forms of tryptophan in ruminants can be a risk. The FEEDAP Panel cannot conclude on the dermal or
ocular irritation and skin sensitisation of L-tryptophan produced by E. coli CGMCC 11674. The additive
poses a risk by inhalation from the exposure to endotoxins for people handling the additive. The use of
L-tryptophan produced by E. coli CGMCC 11674 in animal nutrition does not pose a risk to the
environment. The additive under assessment is regarded as an effective source of the amino acid
L-tryptophan for all non-ruminant species. If the product L-tryptophan is intended for use in ruminants,
it should be protected from ruminal degradation.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Agri Nutrition BV2 for authorisation of the
product L-tryptophan produced by Escherichia coli CGMCC 11674, when used as a feed additive for all
animal species (category: nutritional additive; functional group: amino acids, their salts and
analogues).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 8 September 2016.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product L-tryptophan produced by Escherichia coli CGMCC 11674 for all animal species, when used
under the proposed conditions of use (see Section 3.1.4).
1.2. Additional information
L-Tryptophan (minimum content of 98% on dry matter basis) produced by fermentation with six
strains of E. coli (KCCM 11132P, DSM 25084, FERM BP-11200, FERM BP-11354, CGMCC 7.59 or CGMCC
3667) is currently authorised as a nutritional feed additive for use in all animal species.3 The product
under assessment, L-tryptophan produced by E. coli CGMCC 11674, has not been previously authorised
as feed additive in the European Union (EU).
L-Tryptophan is authorised for use in food,4 cosmetics5 and as a veterinary medicinal product.6,7
L-Tryptophan is described in the European Pharmacopoeia (2017), monograph 01/2017:1272.
The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) published
several opinions on the safety and efﬁcacy of L-tryptophan produced by different strains of E. coli for
all animal species (EFSA FEEDAP Panel, 2013, 2014a,b, 2015a,b, 2016a,b, 2017a,b).
The Panel on Dietetic Products, Nutrition and Allergies (NDA) of EFSA issued a scientiﬁc opinion on
the substantiation of health claims related to L-tryptophan (EFSA NDA Panel, 2011). The Panel on
Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientiﬁc Committee for Food
Safety (VKM) published an opinion on histidine, methionine, S-adenosylmethionine and tryptophan
added to foods and drinks and in food supplements (VKM, 2013) and another on L-tryptophan in food
supplements and energy drinks (VKM, 2016).
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Agri Nutrition BV, Hanzestraat 1, 7006 RH Doetinchem, The Netherlands. Representing Xinjiang Fufeng Biotechnologies Co.,
Ltd.
3 Commission implementing regulation (EU) 2017/873 of 22 May 2017 concerning the authorisation of L-tryptophan produced by
Escherichia coli as feed additive for all animal species. OJ L 134, 23.5.2017, p. 14.
4 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
5 Commission Decision of 9 February 2006 amending Decision 96/335/EC establishing an inventory and a common nomenclature
of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, pp. 1–528.
6 Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classiﬁcation
regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1.
7 Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community
procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin,
repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the
Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council. OL L 152, 16.6.2009, p. 11.
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2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier8 in support of the authorisation request for the use of L-tryptophan minimum 98% produced by
E. coli CGMCC 11674 as an additive for feed and water for drinking in all animal species.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers,
other scientiﬁc reports and experts’ knowledge, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the L-tryptophan produced by E. coli CGMCC 11674 in animal feed.
The Executive Summary of the EURL report can be found in Annex A.9
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of L-tryptophan
minimum 98% produced by E. coli CGMCC 11674 is in line with the principles laid down in Regulation
(EC) No 429/200810 and the relevant guidance documents: Guidance on the identity, characterisation
and conditions of use of feed additives (EFSA FEEDAP Panel, 2017c), Guidance on the characterisation
of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018),
Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel,
2017d), Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP
Panel, 2017e) and Guidance on studies concerning the safety of use of the additive for users/workers
(EFSA FEEDAP Panel, 2012).
3. Assessment
L-Tryptophan minimum 98% produced by E. coli CGMCC 11674 is intended to be used as a
nutritional feed additive under the functional group ‘amino acids, their salts and analogues’ in feed and
water for drinking for all animal species.
3.1. Characterisation
3.1.1. Characterisation of the production organism
The product under assessment is produced by a non-genetically modiﬁed strain of E. coli, deposited
in the China General Microbiological Culture Collection Centre (CGMCC) with accession number CGMCC
11674.11
8 FEED dossier reference: FAD-2016-0032.
9 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep-fad-2016-0032_tryptophan.pdf
10 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
11 Technical dossier/Section II/Annex 2.2.1.2.a.
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3.1.2. Manufacturing process
The dossier contains sufﬁcient information on the production process.
The applicant stated that no antibiotics are used during the production process.16
3.1.3. Characterisation of the active substance/additive
L-Tryptophan (International Union of Pure and Applied Chemistry (IUPAC) name: (2S)-2-amino-3-
(1H-indol-3-yl) propanoic acid; synonyms: (S)-a-amino-1-H-indole-3-propanoic acid, l-a-aminoindole-3-
propionic acid,-l-a-amino-3-indolepropionic acid, 2-amino-3-indolylpropanoic acid, l-b-3-indolylalanine)
has the Chemical Abstracts Service (CAS) No 73-22-3 and European Inventory of Existing Commercial
Chemical Substances (EINECS) No 200-795-6. The chemical formula is C11H12N2O2, the molecular
weight is 204.23 g/mol. The structural formula is given in Figure 1.
The L-tryptophan content of the product is speciﬁed as ≥ 98% on ‘as is’ basis, the other
components being water (< 0.5%) and other amino acids (unspeciﬁed %).17 The analysis of ﬁve
batches of L-tryptophan showed an average content of L-tryptophan of 98.5% ‘as is’ (range 97.6 to
100%),18 moisture was on average 0.7% (range 0.4–1.1%). Tryptophan was below the speciﬁcation in
two of the batches analysed and moisture was above the speciﬁcation in four of the batches analysed.
The amount of identiﬁed material (corresponding to tryptophan) on dry matter basis was on average
99.2% (98.3–100.6).19
The speciﬁc optical rotation measured in three batches ranged from 31.4 to 30.8°,20 which is
within the range described in the European Pharmacopoeia (from 33.0 to 30.0°)21 and conﬁrms the
identity of the L-enantiomer.
3.1.3.1. Impurities
Three batches of the ﬁnal product were analysed heavy metals (lead, cadmium and mercury) and
arsenic. Cadmium ranged from 0.0008 to 0.0042 mg/kg; mercury from 0.031 to 0.044 mg/kg and lead
from 0.02 to 0.08 mg/kg. Arsenic was < 0.2 mg/kg in all cases.22 Dioxins (polychlorinated
dibenzodioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs)), dioxin-like polychlorinated
biphenyls (DL-PCBs) were analysed in three batches and the values ranged 0.11–0.25 ng/kg and 0.13–
0.26 ng/kg, respectively.23
Analysis of the microbial contamination of the ﬁnal product (six batches) indicated that Salmonella
spp. (in 10 g), Enterobacteriaceae and E. coli were absent.24 Three batches were analysed for yeasts
Figure 1: Structural formula of L-tryptophan
16 Technical dossier/Section II/Annex 2.3.k.
17 Technical dossier/Section II.2.1.3.
18 Technical dossier/Section II/Annex 2.1.3a; supplementary information November 2018/Annex 1; and answers to FAD-2016-
0032 SIn 110918, response to question 2. Analytical method Regulation No 152/2009, III, F.
19 Technical dossier/Supplementary information November 2018/Answers to FAD-2016-0032 Sin 110918, response to questions 1
and 2 and Annexes 1 and 2.
20 Technical dossier/Section II/Annex 2.1.4a and Supplementary information July 2018/Annex 4.
21 European Pharmacopoeia 9th edition, monograph 01/2017:1272
22 Technical dossier/Section II/Annex 2.1.4a.
23 Technical dossier/Supplementary information July 2018/Annexes 6.1 to 6.3.
24 Technical dossier/Section II/Annex 2.1.3a and 2.1.4a.
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and ﬁlamentous fungi and the results were negative.25 Mycotoxins levels were analysed in three
batches. The levels of aﬂatoxin, ochratoxin A, zearalenone, fumonisin, deoxinivalenol and citrinin were
all below the limit of detection (LOD) except ochratoxin A that showed values of 6.2 and 7.5 lg/kg in
two of the three batches analysed.26
The antimicrobial activity of one batch of the ﬁnal product was tested against the reference strains
proposed in the Technical guidance of microbial studies (EFSA, 2008). In all cases, the minimum
inhibitory concentration was > 2,500 mg/L.28
1,10-Ethylidene-bis-L-tryptophan (EBT) and 1-methyl-1,2,3,4-tetrahydro-b-carboline-3-carboxylic acid
(MTCA), present in a speciﬁc brand of L-tryptophan produced by fermentation, were implicated in the
eosinophilia–myalgia syndrome (EMS) outbreak that occurred in humans in New Mexico in 1989
(Hertzman et al., 1990). In the product under assessment, the levels of MTCA (three batches) ranged
from 106 to 128 mg/kg and EBT concentrations ranged from 16 to 18 mg/kg.29 As speciﬁed in the
European Pharmacopoeia 9th edition (2017), the maximum permitted content of EBT (impurity A) and
the sum of all other impurities (B-L, including MTCA) in L-tryptophan are 10 mg/kg and 390 mg/kg,
respectively.
Overall, the data on undesirable contaminants (chemical and microbiological) do not give rise to
safety concerns, except for the concentration of the tryptophan impurity EBT, which is further
discussed in the safety section.
3.1.3.2. Physico-chemical characteristics
The additive is a white crystalline powder with a pH value (1% solution measured in three batches)
ranging from 5.1 to 5.8.22 The density is 500 kg/m3.31
The particle size distribution of the ﬁnal product (three batches) was analysed by laser diffraction.32
In all cases 100% (v/v) of the particles were < 100 lm diameter. The fractions of particles having
diameters < 50 and < 10 lm diameter ranged 77–87% (v/v) and 9–15% (v/v), respectively.
The dusting potential analysed in three batches (Stauber–Heubach) ranged from 39 to 53 g/m3.33
3.1.3.3. Stability and homogeneity
The shelf life of three batches of the ﬁnal product was studied under two different temperatures
(25 and 40°C) when stored for 3 months. The samples were stored in sealed plastic bags protected
from light.34 Losses ranged from 0 to 2.3% at 25°C and from 0 to 1.2% at 40°C.35
The stability of the additive (three batches) was studied in a vitamin/mineral premixture also
containing choline chloride (18.4 g/kg).36 The supplemental rate was not described. The premixture
was stored at room temperature in plastic bags protected from light for 6 months. No losses were
observed.
The additive (three batches) was added at a level of 0.3% to a complete mash feed for piglet for
fattening based on barley, soybean meal and wheat containing 0.21% tryptophan.37 The mash feed
25 Technidal dossier/Supplementary information July 2018/Annex 2b.
26 Technical dossier/Section II/Annex 2.1.3a. LOD in µg/kg were 1.7 for aﬂatoxins, 5 for ochratoxin A, 15 for citrinin, 17 for
zearalenone, 25 for fumonisin and 134 for deoxynivalenol.
28 Technical dossier/Section II/Annex 2.2.2.2.
31 Technical dossier/Section II/Table 2.1.5a.
32 Technical dossier/Section II/Annexes 2.1.5 a, b and c.
33 Technical dossier/Section II/Annexes 2.4.3 a, b and c.
34 Technical dossier/Supplementary information July 2018/Answers to FAD-2016-0032 Sin 141016, answer to question 13.
35 Technical dossier/Section II/Annex 2.1.3a.
36 Technical dossier/Section II/Annex 2.1.3a and Annex 2.4.1 feed composition. Supplementary information July 2018/Answer to
question 14 and annex 2.b.
37 Technical dossier/Section II/Annex 2.1.3a and Annex 2.4.1 feed composition. Supplementary information July 2018/Answers to
FAD-2016-0032/answer to question 15.
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was conditioned at 45°C and the pelleting was done at 60°C. Samples of mash and pelleted feed were
subsequently stored in paper bags at room temperature and protected from light. No loss of
tryptophan was observed during storage of the mash feed. In pelleted feed two batches showed a loss
of 4%.
The stability of the product under assessment (three batches) was studied when diluted to a
concentration of 1% in water for drinking and solutions were stored at room temperature for 24 h.38
Only one batch showed a loss of tryptophan of 1%.
The homogeneous distribution of one batch of the additive when supplemented at 0.3% inclusion
level in the mash pelleted feed described above was studied by analysing 10 subsamples.39 The
coefﬁcient of variation of the mean was 2.2%.
3.1.3.4. Physico-chemical incompatibilities in feed
No physico-chemical incompatibilities in feed are expected with other feed additives, medicinal
products or feed materials.
3.1.4. Conditions of use
The current application of L-tryptophan is as a nutritional additive to feed for all animal species and
categories without maximum content in feed or time of administration. According to the applicant, the
additive can be added directly to compound feedingstuffs or via premixtures. It can be added to water
for drinking.40 No inclusion levels are proposed as the requirements in quantitative terms depend on
the species, the physiological state of the animal, the performance level and the environmental
conditions, as well as the amino acid composition of the unsupplemented diet.
3.2. Safety
3.2.1. Safety for the target species
Tolerance studies are not normally required for highly puriﬁed amino acids. Such tolerance studies
with a certain indispensable amino acid will inevitably result in amino acid imbalances, with depression
of feed intake and hence impaired performance and increased nitrogen excretion. The additive
contains on average 99.2% tryptophan and < 1% unidentiﬁed material on a dry matter basis. The
production strain has been identiﬁed at strain level as a E. coli K-12 derivative, no genes of concern
have been identiﬁed and the production strain is sensitive to the antimicrobials listed in the FEEDAP
guidance of 2018. The endotoxin activity These values are
compared with ca. 1,000 IU/mg commonly found in feedingstuffs (Cort et al., 1990). Therefore, at the
usual conditions of use of the additive in feed, the endotoxins added by the additive would be
insigniﬁcant compared with the background in feed.
However, the additive contains concentrations of EBT (up to 18 mg/kg) higher than the limit
(< 10 mg/kg) set for this impurity by the European Pharmacopoeia. The applicant performed a
literature search to demonstrate that the high levels of EBT in the additive do not represent a safety
concern for the target species.41 The database platforms Scopus and Web of Science were searched,
and no restrictions were applied. The search string was ‘eosinophilia AND syndrome AND tryptophan
AND EBT.’ From 51 hits retrieved only 6 were considered relevant (Belongia et al., 1992; Love et al.,
1993; Sato et al., 1995; Takagi et al., 1995; Adachi et al., 2000; Simat et al., 2003). The Panel notes
that there is uncertainty on the association of EBT and other tryptophan-related substances with
adverse effects observed in humans (see Section 3.2.2) and on the relevance of these effects for the
target species. In the absence of reliable data on the target species, the FEEDAP Panel concludes that
the additive cannot be considered safe for the target species unless it complies with the maximum
limits set in the European Pharmacopoeia for the related impurities.
The L-tryptophan requirements of the target animal species and the safety of the use of this
essential amino acid in non-ruminant and ruminant nutrition were summarised in previous opinions of
the EFSA FEEDAP Panel (2013, 2015a).
38 Technical dossier/Section II.2.4.1 and Annex 2.1.3a.
39 Technical dossier/Section II.2.4.2 and Annex 2.1.3a. Supplementary information July 2018/Answers to FAD-2016-0032/answer
to question 16.
40 Technical dossier/Section II.2.5.1.
41 Technical dossier/Supplementary information January 2009/Answers to FAD-2016-0032 Sin.
L-Tryptophan produced by Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2019;17(3):5642
The FEEDAP Panel reiterates (EFSA FEEDAP Panel, 2015a) that ruminal metabolism of unprotected
L-tryptophan may result in the production of toxic quantities of 3-methylindole (skatole), which causes
pulmonary disease (fog fever; emphysema) in cattle and goats. Consequently, using unprotected forms
of tryptophan in ruminants can be a risk.
The FEEDAP Panel recommended in a previous statement that amino acids, their salts and
analogues should generally not be used in water for drinking because of the risk of imbalances and for
hygiene reasons (EFSA FEEDAP Panel, 2010).
3.2.1.1. Conclusions on safety for the target species
The FEEDAP Panel cannot conclude on the safety of L-tryptophan produced by E. coli CGMCC 11674
for the target species due to the tryptophan related impurities as e.g. EBT.
The FEEDAP Panel has concerns on the safety of the simultaneous oral administration of
L-tryptophan via water for drinking and feed.
Using unprotected forms of tryptophan in ruminants can be a risk.
3.2.2. Safety for the consumer
The amino acid L-tryptophan, supplemented to feed, will be incorporated into proteins of tissues
and/or products of animal origin and any of their potential excess will be metabolised and excreted as
urea/uric acid and carbon dioxide. Therefore, the composition of tissues and products of animal origin
will not be affected by the use of L-tryptophan in animal nutrition
The product under assessment is produced by fermentation. Concerns for the consumer would
derive not from the amino acid itself, which will be incorporated into proteins, but from possible
residues from fermentation. The additive contains on average 99.2% tryptophan and < 1%
unidentiﬁed material on a dry matter basis. No concerns have been identiﬁed regarding the production
strain and in the manufacturing process. Nevertheless, the concentrations of EBT ranged from 16 to
18 mg/kg.
The applicant performed a literature search to demonstrate that the high levels of EBT in the
additive do not represent a safety concern for the consumer (see Section 3.2.2). Despite in vivo data
useful to estimate consumer exposure to EBT are not available, in vitro data show that EBT can
compete with tryptophan in the protein synthesis and can be incorporated into proteins (Sidransky
et al., 1994; Buss et al., 1996a,b; Sidransky, 2002). The limited information provided showed that the
occurrence of EMS in humans has been related to several impurities (EBT, MTCA and tryptophan-
related substances). However, there is uncertainty on the association of EBT and/or other tryptophan-
related substances and EMS in humans (Committee on Toxicity (COT), 2004). In the absence of
toxicological data showing a dose–response relationship between exposure to EBT and the adverse
effects observed in humans, an effect level could not be identiﬁed and a health based guidance value
could not be derived for EBT. Therefore, the FEEDAP Panel considers it appropriate to take a
precautionary approach and concludes that the product cannot be considered safe for consumers
unless it complies with the maximum limits set in the European Pharmacopoeia for the related
impurities.
3.2.2.1. Conclusions on safety for the consumer
The FEEDAP Panel cannot conclude on the safety of L-tryptophan produced by E. coli CGMCC 11674
for the consumer due to the tryptophan related impurities as e.g. EBT.
3.2.3. Safety for the user
No studies were submitted to support the safety of the additive under assessment for user/workers.
3.2.3.1. Effects on the respiratory system
The additive under assessment is a ﬁne powder (all particles have a diameter < 100 lm). The
fractions of particles having diameters < 50 and < 10 lm diameter ranged 77–87% (v/v) and 9–15%
(v/v), respectively. The dusting potential ranged from 39 to 53 g/m3. Therefore, inhalation exposure of
users is likely.
The endotoxin activity in the additive was . The scenario used to estimate the
exposure of persons handling the additive to endotoxins in the dust, based on the EFSA Guidance on
user safety (2012), is described in Appendix A. The health based recommended threshold for the
quantity of inhaled endotoxins per working day is 900 IU, derived from provisional occupational
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exposure limits given by the Dutch Expert Committee on Occupational Safety (DECOS) (Health Council
of the Netherlands, 2010) and the Health and Safety Executive (HSE, 2013). Based upon the
calculation of the potential endotoxin content in dust (Wallace et al., 2016), the inhalation exposure
could be up to 8,068 endotoxin IU per 8-h working day, indicating a risk from the exposure to
endotoxins for people handling the additive.
3.2.3.2. Effects on the skin and eyes
In the absence of data, the FEEDAP Panel cannot conclude on the irritation potential of the additive
under assessment for skin or eyes, and on its potential to be a dermal sensitiser.
3.2.3.3. Conclusions on safety for the user
The FEEDAP Panel cannot conclude on the potential dermal or ocular irritation and skin
sensitisation of the product under assessment. The product under assessment poses a risk from the
exposure to endotoxins for people handling the additive.
3.2.4. Safety for the environment
The amino acid L-tryptophan is a physiological and natural component of animals and plants. When
given to animals, it is excreted not as such, but as urea/uric acid, indole-related compounds and
carbon dioxide. The use of the product, L-tryptophan, in animal nutrition would not lead to any
localised increase in the concentration in the environment. It is concluded that the use of the product
L-tryptophan produced by E. coli CGMCC 11674 as a feed additive does not represent a risk to the
environment.
3.3. Efﬁcacy
Efﬁcacy studies are not required for amino acids naturally occurring in the proteins of plants and
animals. The nutritional role of L-tryptophan is well established in the scientiﬁc literature. The additive
under assessment is regarded as an effective source of the amino acid L-tryptophan.
Overdosing of supplemental L-tryptophan may increase skatole and indole in the hind gut, resulting
in boar taint of pork (Zamaratskaia and Squires, 2008).
The efﬁcacy of this essential amino acid in non-ruminant and ruminant nutrition was summarised in
a previous opinion (EFSA FEEDAP Panel, 2014b). The FEEDAP Panel reiterates that, if the product
L-tryptophan is intended for use in ruminants, it should be protected from ruminal degradation.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation42 and Good
Manufacturing Practice.
4. Conclusions
The FEEDAP Panel cannot conclude on the safety of L-tryptophan produced by E. coli CGMCC 11674
for the target species and for the consumer due to the tryptophan-related impurities as e.g. EBT.
The FEEDAP Panel has concerns on the safety of the simultaneous oral administration of
L-tryptophan via water for drinking and feed. Using unprotected forms of tryptophan in ruminants can
be a risk.
The FEEDAP Panel cannot conclude on the dermal or ocular irritation and skin sensitisation of
L-tryptophan produced by E. coli CGMCC 11674. The additive poses a risk by inhalation from the
exposure to endotoxins for people handling the additive.
The use of L-tryptophan produced by E. coli CGMCC 11674 in animal nutrition does not pose a risk
to the environment.
The additive under assessment is regarded as an effective source of the amino acid L-tryptophan
for all non-ruminant species. If the product L-tryptophan is intended for use in ruminants, it should be
protected from ruminal degradation.
42 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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Documentation provided to EFSA
1) L-Tryptophan produced by E. coli for all animal species. August 2016. Submitted by Agri
Nutrition BV.
2) L-Tryptophan produced by E. coli for all animal species. Supplementary information. July
2018. Submitted by Agri Nutrition BV.
3) L-Tryptophan produced by E. coli for all animal species. Supplementary information.
November 2018. Submitted by Agri Nutrition BV.
4) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for L-Tryptophan Produced by Escherichia coli CGMCC 11674.
5) Comments from Member States.
Chronology
Date Event
24/05/2016 Dossier received by EFSA
02/06/2016 Reception mandate from the European Commission
08/09/2016 Application validated by EFSA – Start of the scientiﬁc assessment
14/11/2016 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: manufacturing process,
characterisation of the additive and of the production microorganism, stability and homogeneity
and safety for the user.
08/12/2016 Comments received from Member States
04/01/2017 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
13/07/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
11/09/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Characterisation of the additive,
safety for the target species and for the consumer.
27/11/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
26/02/2019 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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Abbreviations
CAS Chemical Abstracts Service
CFU colony forming unit
CGMCC China General Microbiological Culture Collection Center
COT Committee on Toxicity
CV coefﬁcient of variation
DL-PCB dioxin-like polychlorinated biphenyls
DECOS Dutch Expert Committee on Occupational Safety
DM dry matter
EBT 1,10-ethylidene-bis-L-tryptophan
EINECS European Inventory of Existing Commercial Chemical Substances
EMS eosinophilia–myalgia syndrome
EURL European Union Reference Laboratory
FCC Food Chemical Codex
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GMO EFSA Panel on Genetically Modiﬁed Organisms
HPLC-FD High-Performance Liquid Chromatography equipment coupled with ﬂuorescence detection
HSE Health and Safety Executive
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IUPAC International Union of Pure and Applied Chemistry
LOD limit of detection
MTCA 1-methyl-1,2,3,4-tetrahydro-b-carboline-3-carboxylic acid
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
PCDD polychlorinated dibenzodioxin
PCDF polychlorinated dibenzofuran
RSDr relative standard deviation for repeatability
RSDR relative standard deviation for reproducibility
VKM Norwegian Scientiﬁc Committee for Food Safety
TEQ toxic equivalent
WHO World Health Organization
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Appendix A – Calculation of exposure to endotoxins
Calculation of maximum acceptable levels of exposure from feed additives.
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising
20 seconds = 40 9 20 = 800 s/day. With an uncertainty factor of 2, maximum inhalation exposure
would occur for 2 9 800 = 1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h,
the inhalation volume providing exposure to potentially endotoxin-containing dust would be
0.444 9 1.25 = 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the
dust formed from the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust.
Two key measurements are required to evaluate the potential respiratory hazard associated with
the endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and
the endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in
IU/g)). If data for the dust are not available, the content of endotoxins of the product can be taken
instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential is b
g/m3, then the content of endotoxins of the dust, c IU/m3, is obtained by simple multiplication, a 9 b.
This resulting value is further used for calculation of the potential inhalatory exposure of users to
endotoxins from the additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012).
Table A.1: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli CGMCC 11674, including consideration of using a ﬁlter mask FF P2 or FF
P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product Technical dossier
b Dusting potential (g/m3) 53 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 14,522
d No of premixture batches made/
working day
40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012)
e Time of exposure (s) per production
of one batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012)
d 9 e f Total duration of daily exposure/
worker (s)
800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012)
f 9 g h Reﬁned total duration of daily
exposure/worker (s)
1600
h/3 600 i Reﬁned total duration of daily
exposure (h)
0.44
j Inhaled air (m3) per eight-hour
working day
10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during
exposure per eight-hour
working day
8,068
m Health-based recommended
exposure limit of endotoxin (IU/m3)
per eight-hour working day
90 Health Council of the Netherlands
(2010)
m 9 j n Health-based recommended
exposure limit of total
endotoxin exposure (IU) per
eight-hour working day
900
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Calculation Identiﬁer Description Amount Source
l/10 Endotoxins inhaled (IU) per eight-
hour working day reduced by ﬁlter
mask FF P2 (reduction factor 10)
807
l/20 Endotoxins inhaled (IU) per eight-
hour working day reduced by ﬁlter
mask FF P3 (reduction factor 20)
403
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
of L-Tryptophan Produced by Escherichia coli CGMCC 11674
In the current application, authorisation is sought under Article 4(1) for L-tryptophan produced by
Escherichia coli CGMCC 11674, under the category/functional group 3(c) ‘nutritional additives’/’amino
acids, their salts and analogues’, according to Annex I of Regulation (EC) No 1831/2003. Authorisation
is sought for all animal species. L-Tryptophan is already authorised as a feed additive under Commission
Directive 88/485/EEC of 26 July 1988 amending the Annex to Council Directive 82/471/EEC concerning
certain products used in animal nutrition.
For the quantiﬁcation of L-tryptophan in premixtures, feedingstuffs and water, the Applicant
submitted the ring-trial validated Community method (Commission Regulation (EC) No 152/2009). This
High-Performance Liquid Chromatography equipment coupled with ﬂuorescence detection (HPLC-FD)
method applies for the determination of free (synthetic and natural) and of total (peptide-bound and
free) amino acid in feedingstuffs only. The following performance characteristics were reported for the
quantiﬁcation of tryptophan: a relative standard deviation for repeatability (RSDr) ranging from 0.8 to
1.9% and a relative standard deviation for reproducibility (RSDR) ranging from 1.5 to 6.3%.
For the quantiﬁcation of L-tryptophan in the feed additive, the Applicant submitted the ringtrail
validated EN ISO 13904:2005 based on HPLC-FD and speciﬁcally designed for feedingstuffs. The
standard was further ring-trial validated to assess the performance characteristics of the analytical
method for the determination of the amino acid in feed additives and premixtures thus resulting in the
recent standard EN ISO 13904:2016. The following performance characteristics were reported for the
quantiﬁcation of free tryptophan: RSDr ranging from 0.5 to 5.3% and RSDR ranging from 1.0 to 9.5%.
Based on the performance characteristics presented, the EURL recommends for ofﬁcial control (i)
the ring-trial validated EN ISO 13904:2016 based on reversed phase HPLC-FD, to determine
tryptophan in feed additives and premixtures and (ii) the Community method, based on reversed
phase HPLC-FD, to determine tryptophan in feedingstuffs. In addition, the EURL identiﬁed the
‘L-tryptophan monograph’ of the Food Chemical Codex (FCC) for the characterisation of the feed
additive.
Since the Applicant provided no experimental data to determine L-tryptophan in water, the EURL is
neither able to evaluate nor to recommend a method for ofﬁcial control. Further testing or validation of
the methods to be performed through the consortium of National Reference Laboratories as speciﬁed
by Article 10 (Commission Regulation (EC) No 378/2005) is not considered necessary.
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